{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:29:13Z","timestamp":1794562153819,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Neuroimaging studies have identified distinct \u2018typical\/neocortical\u2019 and \u2018limbic-predominant\u2019 hypometabolic subtypes of AD with different clinical and biomarker characteristics. We investigated associations of these subtypes with postmortem neuropathological measures in an observational study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Antemortem FDG-PET scans of 74 participants from the ADNI autopsy cohort were classified into previously described typical\/neocortical and limbic-predominant subtype patterns. We used Bayesian regression and ANCOVA to test associations between the subtypes and neuropathological features.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Results were inconclusive for Thal phases, Braak stages, CERAD neuritic plaque scores, hippocampal tangle density, and TDP-43 pathology (BF<jats:sub>10<\/jats:sub> between 0.447 and 1.146). However, the limbic-predominant subtype was associated with hippocampal sclerosis (BF<jats:sub>10<\/jats:sub>\u2009=\u20093.842, moderate level of evidence), whereas the typical\/neocortical subtype was associated with Lewy body pathology (BF<jats:sub>10<\/jats:sub>\u2009=\u200910.093, strong level of evidence).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings highlight the influence of AD and non-AD-specific pathologies on neurodegeneration patterns and may provide directions for research into hypometabolic pattern analysis as an indirect marker of comorbid pathology.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01796-6","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T03:36:44Z","timestamp":1753414604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypometabolic subtypes of AD are linked to comorbid hippocampal sclerosis and Lewy body pathology"],"prefix":"10.1186","volume":"17","author":[{"given":"Fedor","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dyrba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel J.","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"10","key":"1796_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","volume":"94","author":"D Ferreira","year":"2020","unstructured":"Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: A systematic review and meta-analysis. Neurology. 2020;94(10):436\u201348.","journal-title":"Neurology"},{"issue":"1","key":"1796_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biopsych.2020.01.016","volume":"88","author":"M Habes","year":"2020","unstructured":"Habes M, Grothe MJ, Tunc B, McMillan C, Wolk DA, Davatzikos C. Disentangling heterogeneity in Alzheimer\u2019s disease and related dementias using Data-Driven methods. Biol Psychiatry. 2020;88(1):70\u201382.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"1796_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785\u201396.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1796_CR4","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.neurobiolaging.2014.04.006","volume":"35","author":"V Kljajevic","year":"2014","unstructured":"Kljajevic V, Grothe MJ, Ewers M, Teipel S. Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer\u2019s disease. Neurobiol Aging. 2014;35(9):1973\u201381.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1796_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-021-00785-9","volume":"13","author":"F Levin","year":"2021","unstructured":"Levin F, Ferreira D, Lange C, Dyrba M, Westman E, Buchert R, et al. Data-driven FDG-PET subtypes of Alzheimer\u2019s disease-related neurodegeneration. Alzheimers Res Ther. 2021;13(1):49.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1796_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/alz.13385","volume":"20","author":"SP Caminiti","year":"2024","unstructured":"Caminiti SP, De Francesco S, Tondo G, Galli A, Redolfi A, Perani D, et al. FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI. Alzheimers Dement. 2024;20(1):159\u201372.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1796_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13195-018-0369-8","volume":"10","author":"C Cerami","year":"2018","unstructured":"Cerami C, Dodich A, Iannaccone S, Magnani G, Santangelo R, Presotto L, et al. A biomarker study in long-lasting amnestic mild cognitive impairment. Alzheimers Res Ther. 2018;10(1):42.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1796_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/ene.14639","volume":"28","author":"G Tondo","year":"2021","unstructured":"Tondo G, Carli G, Santangelo R, Mattoli MV, Presotto L, Filippi M, et al. Biomarker-based stability in limbic-predominant amnestic mild cognitive impairment. Eur J Neurol. 2021;28(4):1123\u201333.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1796_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ana.24493","volume":"78","author":"KA Josephs","year":"2015","unstructured":"Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer\u2019s disease impact clinical features. Ann Neurol. 2015;78(5):697\u2013709.","journal-title":"Ann Neurol"},{"issue":"11","key":"1796_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1474-4422(17)30284-3","volume":"16","author":"KA Josephs","year":"2017","unstructured":"Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer\u2019s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16(11):917\u201324.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1796_CR11","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/alz.12763","volume":"19","author":"MJ Grothe","year":"2023","unstructured":"Grothe MJ, Moscoso A, Silva-Rodriguez J, Lange C, Nho K, Saykin AJ, et al. Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC. Alzheimers Dement. 2023;19(4):1234\u201344.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1796_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327.","journal-title":"Brain"},{"issue":"3","key":"1796_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/awaa438","volume":"144","author":"JL Robinson","year":"2021","unstructured":"Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, et al. The development and convergence of co-pathologies in Alzheimer\u2019s disease. Brain. 2021;144(3):953\u201362.","journal-title":"Brain"},{"issue":"2","key":"1796_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2967\/jnumed.122.264213","volume":"64","author":"J Silva-Rodriguez","year":"2023","unstructured":"Silva-Rodriguez J, Labrador-Espinosa MA, Moscoso A, Scholl M, Mir P, Grothe MJ. Differential effects of Tau stage, Lewy body pathology, and Substantia Nigra degeneration on (18)F-FDG PET patterns in clinical Alzheimer disease. J Nucl Med. 2023;64(2):274\u201380.","journal-title":"J Nucl Med"},{"issue":"11","key":"1796_CR15","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1093\/brain\/awad194","volume":"146","author":"J Silva-Rodriguez","year":"2023","unstructured":"Silva-Rodriguez J, Labrador-Espinosa MA, Moscoso A, Scholl M, Mir P, Grothe MJ. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology. Brain. 2023;146(11):4520\u201331.","journal-title":"Brain"},{"issue":"12","key":"1796_CR16","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1002\/alz.13164","volume":"19","author":"D Tosun","year":"2023","unstructured":"Tosun D, Thropp P, Southekal S, Spottiswoode B, Fahmi R. Profiling and predicting distinct Tau progression patterns: an unsupervised data-driven approach to flortaucipir positron emission tomography. Alzheimers Dement. 2023;19(12):5605\u201319.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1796_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2015.0606","volume":"72","author":"EJ Chung","year":"2015","unstructured":"Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical features of Alzheimer disease with and without Lewy bodies. JAMA Neurol. 2015;72(7):789\u201396.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1796_CR18","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29(8):1964\u201370.","journal-title":"Nat Med"},{"issue":"4","key":"1796_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3233\/JAD-150814","volume":"49","author":"C Lange","year":"2016","unstructured":"Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R. Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive Impairment-to-Alzheimer\u2019s disease conversion. J Alzheimers Dis. 2016;49(4):945\u201359.","journal-title":"J Alzheimers Dis"},{"key":"1796_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neurobiolaging.2023.12.003","volume":"135","author":"F Levin","year":"2024","unstructured":"Levin F, Grothe MJ, Dyrba M, Franzmeier N, Teipel SJ. Longitudinal trajectories of cognitive reserve in hypometabolic subtypes of Alzheimer\u2019s disease. Neurobiol Aging. 2024;135:26\u201338.","journal-title":"Neurobiol Aging"},{"issue":"12","key":"1796_CR21","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863\u201372.","journal-title":"Neurology"},{"key":"1796_CR22","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/alz.053735","volume":"17","author":"MJ Grothe","year":"2021","unstructured":"Grothe MJ, Moscoso A, Ashton NJ, Zetterberg H, Blennow K, Sch\u00f6ll M. Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer\u2019s disease neuropathology. Alzheimer\u2019s Dement. 2021;17:S5.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"8","key":"1796_CR23","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Rossi M, Hall S, Quadalti C, Mattsson-Carlgren N, Dellavalle S, et al. Cognitive effects of lewy body pathology in clinically unimpaired individuals. Nat Med. 2023;29(8):1971\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"1796_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502\u201316.","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"1796_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","volume":"6","author":"LE Gibbons","year":"2012","unstructured":"Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517\u201327.","journal-title":"Brain Imaging Behav"},{"issue":"1","key":"1796_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3758\/s13423-017-1323-7","volume":"25","author":"EJ Wagenmakers","year":"2018","unstructured":"Wagenmakers EJ, Love J, Marsman M, Jamil T, Ly A, Verhagen J, et al. Bayesian inference for psychology. Part II: example applications with JASP. Psychon Bull Rev. 2018;25(1):58\u201376.","journal-title":"Psychon Bull Rev"},{"issue":"1","key":"1796_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/acn3.51238","volume":"8","author":"SJ Teipel","year":"2021","unstructured":"Teipel SJ, Temp AGM, Levin F, Dyrba M, Grothe MJ. Association of PET-based stages of amyloid deposition with neuropathological markers of Abeta pathology. Ann Clin Transl Neurol. 2021;8(1):29\u201342.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1796_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1796_CR29","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/WNL.0000000000200573","volume":"99","author":"R Mohanty","year":"2022","unstructured":"Mohanty R, Ferreira D, Frerich S, Muehlboeck JS, Grothe MJ, Westman E. Neuropathologic features of antemortem Atrophy-Based subtypes of Alzheimer disease. Neurology. 2022;99(4):e323\u201333.","journal-title":"Neurology"},{"issue":"1","key":"1796_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/alz.13447","volume":"20","author":"D Tosun","year":"2024","unstructured":"Tosun D, Yardibi O, Benzinger TLS, Kukull WA, Masters CL, Perrin RJ, et al. Identifying individuals with non-Alzheimer\u2019s disease co-pathologies: A precision medicine approach to clinical trials in sporadic alzheimer\u2019s disease. Alzheimers Dement. 2024;20(1):421\u201336.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1796_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00401-012-1044-y","volume":"124","author":"NJ Janocko","year":"2012","unstructured":"Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, et al. Neuropathologically defined subtypes of Alzheimer\u2019s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol. 2012;124(5):681\u201392.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1796_CR32","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1038\/s41467-024-49402-x","volume":"15","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek SE, Vogel JW, Collij LE, Serrano GE, Tremblay C, Young AL, et al. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type alpha-synuclein pathology. Nat Commun. 2024;15(1):5133.","journal-title":"Nat Commun"},{"issue":"4","key":"1796_CR33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/brain\/awy049","volume":"141","author":"H Botha","year":"2018","unstructured":"Botha H, Mantyh WG, Murray ME, Knopman DS, Przybelski SA, Wiste HJ, et al. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain. 2018;141(4):1201\u201317.","journal-title":"Brain"},{"issue":"1","key":"1796_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/alz.12797","volume":"19","author":"MW Weiner","year":"2023","unstructured":"Weiner MW, Veitch DP, Miller MJ, Aisen PS, Albala B, Beckett LA, et al. Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer\u2019s Disease Neuroimaging Initiative 4. Alzheimers Dement. 2023;19(1):307\u201317.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01796-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01796-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01796-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:33:11Z","timestamp":1757284391000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01796-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01796-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data collection and sharing in ADNI was approved by the Institutional Review Board of each participating institution and all procedures involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from all ADNI participants and\/or authorized representatives before any protocol-specific procedures were carried out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJT served as member of advisory boards of Lilly, Eisai, and Biogen, and is member of the independent data safety and monitoring board of the study ENVISION (Biogen). FL, MD, MJG have no disclosures to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}